A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors
Main Authors: | Leijen, S, Soetekouw, P, Jeffry Evans, T, Nicolson, M, Schellens, J, Learoyd, M, Grinsted, L, Zazulina, V, Pwint, T, Middleton, M |
---|---|
格式: | Journal article |
出版: |
2011
|
相似書籍
-
A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors.
由: Leijen, S, et al.
出版: (2011) -
DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma
由: Gupta, A, et al.
出版: (2013) -
AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study
由: Dummer, R, et al.
出版: (2008) -
MEK1/2 blockade by AZD6244 (ARRY-142886) inhibits tumor growth and progression in an orthotopic human lung adenocarcinoma model with enhanced efficacy when combined with cediranib
由: Takahashi, O, et al.
出版: (2009) -
Author Correction: Targeting inhibition of extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) suppresses growth and angiogenesis of gastric cancer
由: Jin-Hang Gao, et al.
出版: (2022-03-01)